Biological Polymerase Chain Reaction (PCR) Technology Market Report 2026

The biological polymerase chain reaction (pcr) technology market size has grown rapidly in recent years. It will grow from $16.62 billion in 2025 to $18.31 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to expansion of molecular diagnostics adoption, increasing use of pcr in infectious disease testing, growth of genomic research activities, rising demand for accurate nucleic acid amplification, improvements in thermal cycler technologies.

The biological polymerase chain reaction (pcr) technology market size is expected to see strong growth in the next few years. It will grow to $26.69 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growing adoption of point-of-care pcr systems, increasing use of pcr in oncology and genetic testing, expansion of personalized medicine, rising investments in laboratory automation, increasing demand for rapid diagnostic solutions. Major trends in the forecast period include increasing adoption of real-time and digital pcr techniques, rising demand for high-sensitivity molecular diagnostics, growing integration of pcr data analysis software, expansion of multiplex and high-throughput pcr applications, enhanced focus on workflow automation.

The rising incidence of infectious diseases is expected to drive the growth of the biological polymerase chain reaction (PCR) technology market going forward. Infectious diseases are conditions caused by bacteria, viruses, fungi, or parasites. The increasing incidence of infectious diseases is fueled by growing global travel, which facilitates faster and wider spread of pathogens across regions. Biological polymerase chain reaction (PCR) technology supports the management of infectious diseases by enabling rapid and accurate pathogen detection, allowing early diagnosis, timely treatment, and effective outbreak control. For instance, in December 2024, according to the World Health Organization, a Switzerland-based intergovernmental agency, malaria, a major infectious disease, caused an estimated 263 million cases globally in 2023, up from approximately 252 million cases in 2022, with a case incidence of 60.4 per 1,000 population at risk, up from 58.6 in 2022, 597,000 deaths, and 94 percent of cases and 95 percent of deaths occurring in the WHO African Region. Therefore, the rising incidence of infectious diseases is fueling the growth of the biological polymerase chain reaction (PCR) technology market.

Major companies operating in the biological polymerase chain reaction (PCR) technology market are focusing on technological innovations, such as digital PCR assay kits, to enable precise and efficient quantification of DNA and RNA for biopharma research, cell and gene therapies, and food safety applications. Digital PCR assay kits are laboratory reagent kits used to perform highly sensitive and accurate DNA or RNA quantification using digital PCR technology. For instance, in November 2023, QIAGEN, a Netherlands-based molecular biology solutions provider, launched the QIAcuity Digital PCR Kits along with updated QIAcuity software to broaden applications in biopharma and food-safety testing. These kits employ optimized reagents and consumables to partition nucleic acid samples into thousands of nanoliter-scale reactions, enabling sensitive detection and quantification of rare variants or pathogens. The updated software provides automated analysis, workflow guidance, and data visualization for easier interpretation. Key features include high sensitivity, wide dynamic range, multiplexing capability, and user-friendly operation. Applications span gene expression analysis, mutation detection, microbial testing, and quality control, offering enhanced accuracy, reduced hands-on time, and reliable low-copy detection across research and regulatory settings.

In July 2025, Bio-Rad Laboratories Inc., a US-based life sciences research and clinical diagnostics company, acquired Stilla Technologies SA for an undisclosed amount. Through this acquisition, Bio-Rad aims to strengthen its position in the digital PCR market and expand molecular diagnostics capabilities using Stilla’s advanced crystal digital PCR technology. Stilla Technologies SA is a France-based provider of biological polymerase chain reaction (PCR) technology.

Major companies operating in the biological polymerase chain reaction (pcr) technology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Eppendorf AG, Cepheid Inc., Bio-Techne Corporation, GenScript Biotech Corporation, Takara Bio Inc., Promega Corporation, Analytik Jena GmbH+Co. KG, New England Biolabs Inc., Enzo Biochem Inc., LGC Biosearch Technologies Inc., Bioline Reagents Ltd., Illumina Inc., Abbott Laboratories.

North America was the largest region in the biological polymerase chain reaction (PCR) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biological polymerase chain reaction (pcr) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biological polymerase chain reaction (pcr) technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biological PCR technology market by increasing costs of imported thermal cyclers, optical detection systems, reagents, enzymes, plastic consumables, and analytical software. Diagnostic and research laboratories in North America and Europe are most affected due to reliance on imported high-precision instruments, while Asia-Pacific faces cost pressures in manufacturing and export. These tariffs are raising testing costs and delaying equipment upgrades. However, they are also encouraging domestic reagent production, local instrument assembly, and innovation in cost-optimized PCR platforms.

The biological polymerase chain reaction (pcr) technology market research report is one of a series of new reports that provides biological polymerase chain reaction (pcr) technology market statistics, including biological polymerase chain reaction (pcr) technology industry global market size, regional shares, competitors with a biological polymerase chain reaction (pcr) technology market share, detailed biological polymerase chain reaction (pcr) technology market segments, market trends and opportunities, and any further data you may need to thrive in the biological polymerase chain reaction (pcr) technology industry. This biological polymerase chain reaction (pcr) technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biological polymerase chain reaction (PCR) technology is a laboratory method used to create multiple copies of a specific DNA segment from a minimal starting amount. It works through repeated temperature changes that separate DNA strands, allow short primer sequences to bind, and enable enzymes to synthesize new DNA strands. This cyclical process rapidly produces a large quantity of the target DNA with high precision and accuracy, making it an essential technique for studying genetic material.

The primary product types of biological polymerase chain reaction (PCR) technology are reagents, consumables, and software and services. Reagents refer to chemical substances used in PCR reactions to detect, amplify, or quantify DNA or RNA. The technology employs multiple techniques, including real-time PCR, conventional PCR, digital PCR, reverse transcription PCR, hot-start PCR, multiplex PCR, and others. These are applied in various applications such as diagnostics, genotyping, nucleic acid detection, gene expression analysis, nucleic acid synthesis, genetic sequencing, environmental testing, and standard validation or verification. They serve a wide range of end users, including hospital laboratories, diagnostic laboratories, academic and government organizations, and pharmaceutical and biotechnology companies.

The biological polymerase chain reaction (PCR) technology market consists of revenues earned by entities by providing services such as DNA amplification, genetic testing, and pathogen detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The biological polymerase chain reaction (PCR) technology market also includes sales of enzymes, primers, probes, and thermal cyclers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.